肌电生物反馈治疗儿童青少年排尿功能障碍:随机试验的系统评价与Meta分析
该系统评价与Meta分析纳入4项随机对照试验共244例患儿,评估肌电生物反馈(EMGBF)治疗排尿功能障碍(DV)的疗效。结果显示EMGBF显著提高最大尿流率、恢复正常排尿流模式、减少残余尿并改善遗尿,对膀胱输尿管反流(VUR)的初步数据提示可能获益但证据有限。
要点
- EMGBF可显著改善患儿最大尿流率、排尿模式、残余尿及遗尿。
- VUR亚组数据提示EMGBF可能促进反流缓解,但样本小且非随机。
- EMGBF耐受性良好,但需更高质量试验确认VUR获益并优化方案。
核心结论
- EMGBF是治疗儿童青少年排尿功能障碍的有效且耐受性良好的干预措施。
- EMGBF可改善泌尿系统症状、尿动力学参数及感染率。
- 对VUR的初步获益需进一步高质量试验确认并优化治疗方案。
研究设计与样本
- 系统评价与Meta分析,纳入随机对照试验评估EMGBF治疗儿童青少年DV。
- 检索7个数据库(Cochrane CENTRAL、PubMed/MEDLINE、EMBASE、Scopus、Web of Science、Livivo、LILACS)至2025年1月。
- 同时检索Google Scholar、ProQuest和medRxiv灰色文献。
- 共纳入4项随机对照试验,总计244例患者。
主要发现
- EMGBF显著增加最大尿流率(MD: 4.69; 95% CI: 1.06-8.31)。
- EMGBF显著使排尿流模式正常化(RR: 2.70; 95% CI: 1.43-5.10)。
- EMGBF显著减少排尿后残余尿(MD: 11.11; 95% CI: 2.38-19.84)。
- EMGBF显著改善遗尿(RR: 2.34; 95% CI: 1.05-5.20)。
- 17例VUR患者亚组中,干预组6个月和1年缓解率分别为88.8%和77.7%,对照组为37.5%和12.5%。
关键数值与推荐
- 最大尿流率MD为4.69(95% CI: 1.06-8.31)。
- 排尿流模式正常化RR为2.70(95% CI: 1.43-5.10)。
- 排尿后残余尿MD为11.11(95% CI: 2.38-19.84)。
- 遗尿改善RR为2.34(95% CI: 1.05-5.20)。
- VUR亚组中仅1例IV级反流患者未缓解,但样本量有限且非随机。
临床怎么用
- EMGBF可作为儿童青少年排尿功能障碍的有效治疗选择。
- 治疗可能改善尿流率、残余尿、遗尿及感染率。
- 对合并VUR的患者,EMGBF可能促进反流缓解但需谨慎解读。
局限性
- 仅纳入4项随机对照试验,总样本量244例有限。
- VUR特异性结局分析样本量小(17例)且缺乏随机化。
- VUR缓解率数据应谨慎解读,需进一步高质量试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy of electromyographic biofeedback (EMGBF) in the treatment of dysfunctional voiding (DV) in children and adolescents by synthesizing evidence from randomized controlled trials. METHODS: We conducted a systematic review and meta-analysis of randomized and controlled trials evaluating EMGBF therapy in pediatric patients diagnosed with DV. Searches were performed across seven databases (Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, EMBASE, Scopus, Web of Science, Livivo, and LILACS) up to January 2025. Gray literature was also searched using Google Scholar, ProQuest, and medRxiv. RESULTS: Four randomized controlled trials were included, totaling 244 patients. The meta-analysis showed that EMGBF therapy significantly increased maximum urinary flow rate (MD: 4.69; 95% CI: 1.06-8.31), normalized voiding flow patterns (RR: 2.70; 95% CI: 1.43-5.10), reduced postvoid residual urine (MD: 11.11; 95% CI: 2.38-19.84), and improved enuresis (RR: 2.34; 95% CI: 1.05-5.20). Additionally, a subset of 17 patients with vesicoureteral reflux (VUR) was evaluated. Among those who underwent EMGBF, VUR resolution was observed in all but one patient with grade IV reflux. Reported resolution rates were 88.8% at 6 months and 77.7% at 1 year in the intervention group, compared with 37.5% and 12.5%, respectively, in the control group. However, these findings should be interpreted with caution given the limited number of patients and lack of randomization for VUR-specific outcomes. CONCLUSION: EMGBF is an effective and well-tolerated intervention for treating dysfunctional voiding in children and adolescents. Benefits include improvements in urinary symptoms, urodynamic parameters, and infection rates. Although preliminary findings suggest a possible positive effect on VUR, further high-quality trials are warranted to confirm these observations and to optimize therapeutic protocols.
引用
- Passos CL, Mendes Souza MB, Corrêa Leite MT, et al. Efficacy of Electromyographic Biofeedback for Dysfunctional Voiding in Children and Adolescents: A Systematic Review and Meta-analysis of Randomized Trials. Urology. 2025. PMID: 40865572. doi:10.1016/j.urology.2025.08.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。